Tetracaine oral gel in patients treated with radiotherapy for head-and-neck cancer: Final results of a phase II study

Conclusion: Tetracaine oral gel administration seemed feasible and safe while reducing RT-induced mucositis-related oral pain in a sizeable proportion of treated head-and-neck cancer patients. A trial designed to compare efficacy of this gel vs. standard treatment is warranted.